Daré Bioscience Receives QIDP Designation from the FDA for DARE-BV1 for the Treatment of Bacterial Vaginosis

NEXT STORY
Gritstone Oncology Reports Second Quarter 2019 Financial Results and Recent Highlights
PREV STORY
Onconova Therapeutics and Mission Bio Partner to Advance Precision Oncology Clinical Trials Employing Single-Cell Genomics
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Preliminary Results from Quell Chronic Low Back Pain Study to be Presented at World Institute of Pain World Congress

WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported that ...

author_avatar
NASDAQ Market News

Athenex, Inc. Announces Approval of Tax Incentives from State of New York for the Dunkirk Facility

BUFFALO, N.Y., July 27, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical ...

author_avatar
NASDAQ Market News

Immunocore strengthens IP position in the field of TCR-based therapeutics

PRESS RELEASE Immunocore strengthens IP position in the field of TCR-based therapeutics Notice of ...

author_avatar
NASDAQ Market News